Closed Loop Medicine’s Board brings together extensive experience from the life sciences, healthcare, digital health and technology sectors.

Kate takes over as CEO from our visionary founder, Hakim Yadi, as we move into a new page in CLM’s evolution.
Since joining Closed Loop Medicine as Chief Operating Officer in 2023, Kate has played a pivotal role in leading collaboration across our multi-disciplinary team whilst working closely with current and future commercial partners to drive delivery of Closed Loop Medicine’s products to market.  As we ready ourselves to launch our new GLP1 dose optimisation products in the UK and US, we require a leader with exceptional commercial and operational leadership skills to drive this work forward.
Kate has extensive strategic business experience, including over 15 years in healthcare. In her previous role, Kate was Chief Delivery Officer at ieso Digital Health, where she led product, design, clinical trial operations, commercial, regulatory and program management functions. During that time, Kate secured ieso’s first commercial partnerships and launched its first medical device; demonstrating capability that helped secure $53m Series B investment. Prior to this, Kate was a Partner for PA Consulting, during which time she built and led a healthcare system transformation consulting business worth over £10m p.a. She holds a Masters in Mathematics from The University of Manchester.

Dr Paul Goldsmith was awarded a triple 1st from Cambridge and a clinical scholarship from Oxford. Following general medical  training, he sub-specialised in neurology, before completing a PhD in a development biology lab, taking a systems biology approach to understanding human disease. He was the principal founder of DanioLabs Ltd in 2002, which utilised disease modeling for systematic drug repurposing, established discovery programmes in several areas and generated a product pipeline, the most advanced of which now has positive Phase 2 data.

He was then part of the team that reinvigorated Psychology Online Ltd, a digital health company, with a new business plan, management team and financing. He co-founded Rubrum Ltd in 2012 to provide semi-automated healthcare provision in insomnia, pain and COPD to the NHS and other markets through a proprietary online platform and was NED there until 2014. He was also co-founder of Vastrata Ltd, which focused on reprofiling and repurposing, with a virtual business model.

He also has extensive NHS operational and strategic experience, including being  NHS England Northern Strategic Clinical Networks (SCN) neuro lead (to May 16), and sitting on a NHS England Urgent and Emergency Care Vanguard  and the north Clinical Senate.

Paul is also a Non Executive Director of the UK Medicines & Healthcare products Regulatory Agency (MHRA).

He has in excess of 50 peer reviewed publications and patent applications.

Luba Greenwood is a distinguished executive, investor, and company builder with over 20 years of experience in the healthcare and tech sectors. Luba has served as the Chief Executive Officer and Chair of the Board of Kojin Therapeutics, a leader in ferroptosis. She currently serves as the Managing Partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital (BSC), which she has founded, investing and building companies across therapeutics, diagnostics, and digital sectors. She has also served as a lecturer at Harvard University in the School of Engineering and Applied Sciences. Ms. Greenwood has extensive board experience globally and serves on public and private boards, across multiple industries, including healthcare and tech, and has successfully contributed to the growth and profitability of numerous organizations, bringing her operational, industry, and financing expertise.

Clare Terlouw is Head of LifeArc Ventures, responsible for developing and implementing a strategy for LifeArc’s investments across the life science sector. She is the head of the investment team and a member of the Early Ventures Investment Committee.  Clare oversees the Early Ventures strategy at LifeArc, which is a seed to Series A investment strategy, with the ability to further fund select companies into later rounds of funding. LifeArc’s investment strategy is to seek to generate positive impact on patients and financial returns by investing in early translational sciences and technologies in areas of high unmet patient need.

Clare was previously at Syncona Investment Management Ltd, a FTSE250 healthcare investment trust, where she was Head of Corporate Development. Syncona founds and builds life sciences companies to deliver transformational treatments to patients.  She has 15 years of biotech and healthcare financing experience as an investment banker in the City of London, with significant expertise in growth funding for innovative life sciences companies in the private and public markets.

Clare is also a board member of the BioIndustry Association and a non-executive director of Stevenage Bioscience Catalyst.

Joanna represents BGF’s investment on Closed Loop Medicine’s Board. Joanna has been active in the life sciences sector for over 20 years, as a CEO, Non-Executive Chair, Board Director, and Chair of UK government health innovation funding streams. She has experience in operating roles in SMEs, startups, global biotech, and investment banking in the UK and US, and has also worked as an advisor to investment funds in the sector.

David Van Sickle, PhD, was the co-founder and CEO of Propeller Health, a respiratory digital health and therapeutics company, which pioneered the application of digital technology to chronic disease management and pharmaceutical therapy.

In 2019, the company was acquired by ResMed (NYSE: RMD). David continued to lead the business until 2021 when he transitioned to a role as an Entrepreneur-in-Residence.

From 2017-2020, he served as a founding board member of the Digital Therapeutics Alliance, a 501(c)(6) non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics.

David received a PhD in medical anthropology from the University of Arizona in 2004. Between 2004-6, he was an Epidemic Intelligence Service officer at the US Centers for Disease Control and Prevention. From 2006 to 2009, David was a Robert Wood Johnson Foundation Health and Society Scholar at the University of Wisconsin School of Medicine and Public Health. In 2010, he was named a Champion of Change by the Obama administration for work on technology and innovation.

Paul is an established leader within the digital healthcare industry, having co-founded Lemonaid Health, one of the first national direct-to-consumer telehealth apps in the US, and led the Company as CEO through to its acquisition by consumer genetics and research company, 23andMe, for $400 million in 2021. Paul then became VP and General Manager, and later COO, of the wider 23andMe consumer business, which includes Lemonaid Health, providing its innovative telemedicine platform to advance 23andMe’s vision of individualized primary care. Prior to moving to the US, Paul was Head of Online at McKesson UK, where he was responsible for the online P&L and all digital activity for the Group’s brands, including Lloyds Pharmacy. In 2010, as UK Managing Director, he launched the Zooplus business in the UK, Europe’s leading online pet shop. Paul is an advisor to several technology-first companies and leading venture funds, he is a CEO coach and an active angel investor.